[ad_1]
The average one-year price target for Rhythm Pharmaceuticals (FRA:1RV) has been revised to 34.61 / share. This is an decrease of 8.46% from the prior estimate of 37.81 dated April 6, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 24.74 to a high of 51.45 / share. The average price target represents an increase of 90.16% from the latest reported closing price of 18.20 / share.
See our leaderboard of companies with the largest price target upside.
What is the Fund Sentiment?
There are 200 funds or institutions reporting positions in Rhythm Pharmaceuticals. This is a decrease of 10 owner(s) or 4.76% in the last quarter. Average portfolio weight of all funds dedicated to 1RV is 0.25%, an increase of 13.58%. Total shares owned by institutions increased in the last three months by 1.02% to 71,839K shares.
What are Other Shareholders Doing?
Primecap Management holds 6,911K shares representing 12.18% ownership of the company. In it’s prior filing, the firm reported owning 7,027K shares, representing a decrease of 1.67%. The firm increased its portfolio allocation in 1RV by 10.60% over the last quarter.
Baker Bros. Advisors holds 6,355K shares representing 11.20% ownership of the company. In it’s prior filing, the firm reported owning 6,063K shares, representing an increase of 4.59%. The firm increased its portfolio allocation in 1RV by 14.24% over the last quarter.
Federated Hermes holds 6,304K shares representing 11.11% ownership of the company. In it’s prior filing, the firm reported owning 6,307K shares, representing a decrease of 0.04%. The firm increased its portfolio allocation in 1RV by 12.14% over the last quarter.
Ra Capital Management holds 5,516K shares representing 9.72% ownership of the company. In it’s prior filing, the firm reported owning 5,471K shares, representing an increase of 0.82%. The firm increased its portfolio allocation in 1RV by 13.92% over the last quarter.
Goldman Sachs Group holds 5,202K shares representing 9.17% ownership of the company. In it’s prior filing, the firm reported owning 4,777K shares, representing an increase of 8.16%. The firm increased its portfolio allocation in 1RV by 25.31% over the last quarter.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
Source link
